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In the present work, a comparison of the financial economic structure of two companies 
in the pharmaceutical industry (Spanish) will be carried out, in particular, Pharma Mar 
S.A. and Grifols S.A. 
For this analysis, the annual accounts of each company will be used to do this, which 
are considered reliable since they have obtained a favorable evaluation by the auditors. 
In this analysis we will analyze the financial structure of each company, the profitability, 
the maturity period of each company and some ratio (according to its structure and 
liquidity). 
Finally, the conclusion reached is detailed through the results obtained in each of the 




















2. Global Vision of the Pharmaceutical Sector……………………………………………………………...11 
3. The Pharmaceutical Sector in Spain…………………………………………………………………………..14 
4. History of the Companies under analysis…………………………………………………………….…….17 
 Pharma Mar S.A………………………………………………………………………………………..….17 
 Grifols S.A……………………………………………………………………………………………..……..19 
5. Patrimonial Analysis………………………………………………………………………………………………....22 
 Vertical Index……………………………………………………………………………………………….23 
 Horizontal Index………………………………………………………………………………………..….27 
6. Analysis of the “Fondo de Maniobra” and operational financing needs………………..….29 
7. Profitability Analysis……………………………………………………………………………………….…………31 
 Economic Profitability………………………………………………………………………....……….31 
 Financial Profitability………………………………………………………………………...…………34 
 Threshold of Profitability…………………………………………………………….……..………..36 
8. Period of  maduration…………………………………………………………………………….……….……….38 
 Economic……………………………………………………………………………………….……………38 
 Financial…………………………………………………………………………………………....………..38 
9. Analysis of the financial structure using ratios……………………………………………....…………41 
 Indebtedness…………………………………………………………………………………..……..……41 
 Solvency………………………………………………………………………………………….…..………44 
10. Analysis by means of liquidity ratios……………………………………………………………..…..……..45 
 Current Ratio………………………………………………………………………….……………..…….45 









Index of figures 
Figure 1: Evolution of drug production costs…………………………………………………………………………………12 
Figure 2: Volume of sales of the pharmaceutical industry in different areas of the world between 2011 
and 2020 (thousands of dollars)……………………………………………………………………………………….…………13 
Figure 3: General characteristics of the pharmaceutical industry (Pharmaindustry)…………………………14 
Figure 4: Evolution of I+D expenses 2009-2016 in Spain………………………………………………………………..15  
Figure 5: National Institute of Statistics. Innovation in companies……………………………………….…………15 
Figure 6: Investment in Research and Development depending on the Autonomous Community (Spain)…16 
Figure 7: Subsidiaries of the company Pharma Mar S.A………………………………………………………………...18 
Figure 8: Vertical analysis of Pharma Mar assets………………………………………………………………………….24 
Figure 9: Vertical analysis of Pharma Mar liabilities and equity…………………………………………….………..25 
Figure 10: Vertical analysis of Grifols assets………………………………………………………………………………...26 
Figure 11: Vertical analysis of Grifols liabilities and equity……………………………………………………………..27 
Figure 12: Horizontal analysis Pharma Mar…………………………………………………………………………………..28 
Figure 13: Horizontal analysis Grifols……………………………………………………………………………………………28 
Figure 14: Analysis of maneuvering fund of Pharma Mar…................................................................29 
Figure 15: Analysis of operating needs of Pharma Mar………………………………………………………………….29 
Figure 16: Analysis of maneuvering fund of Grifols……………………………………………………………………….30 
Figure 17: Analysis of operating needs of Grifols………………………………………………………………………….30 
Figure 18: Economic profitability formula…………………………………………………………………………………….31 
Figure 19: Economic profitability of Pharma Mar……………………………………………………………………….…31 
Figure 20: Economic profitability of Grifols…………………………………………………………….…………………….32 
Figure 21: Verification of economic profitability……………………………………………………………………………33 
7 
 
Figure 22: Annual variation of economic profitability. ………………………………………………………………33 
Figure 23: Financial profitability formula. ……………………………………………………………………………….34 
Figure 24: Comparation between economic and financial profitability formula. ………………………….34 
Figure 25: Financial profitability of Pharma Mar. ……………………………………………………………………..35 
Figure 26: Financial profitability of Grifols. ……………………………………………………………………………..36 
Figure 27: threshold of profitability formula. …………………………………………………………………………..37 
Figure 28: Analysis of threshold of profitability. ………………………………………………………………………37 
Figure 29: outline of the maturation period. ……………………………………………………………………………38 
Figure 30: Maduration period of Pharma Mar. …………………………………………………………………………39 
Figure 31: Maduration period of Grifols. ………………………………………………………………………………….40 
Figure 32: Debt ratio formula. ………………………………………………………………………………………….........42 
Figure 33: Analisys debt ratio of Pharma Mar. …………………………………………………………………………..42 
Figure 34: Analysis between short and long term in the debt of Pharma Mar. ……………………………..43 
Figure 35: Analisys debt ratio of Grifols. …………………………………………………………………………………..43 
Figure 36: Analysis between short and long term in the debt of Grifols. ………………………………………44 
Figure 37: Solvency ratio formula. ……………………………………………………………………………………………44 
Figure 38: Analisys between solvency in Pharma Mar and Grifols. ………………………………………………45 
Figure 39: Liquidity ratio formula. …………………………………………………………………………………………….45 
Figure 40: Analisys the liquidity ratio in Pharma Mar………………………………………………………………….46 
Figure 41: Analisys the liquidity ratio in Grifols. ………………………………………………………………………...47 
Figure 42: Acid test ratio formula. …………………………………………………………………………………………...47 
Figure 43: Analisys the acid test in Pharma Mar. ……………………………………………………………………….48 































The present work has the purpose of making an economic-financial comparison 
between two Spanish companies that belong to the pharmaceutical industry (CNAE 
2120), more specifically we will focus on Pharma Mar S.A. and Grifols S.A. To carry out 
this comparison, we have the annual accounts of each company and the period to be 
evaluated is from 2016 to 2018. 
According to Azofra (1995), the economic-financial analysis of a company is the 
process that tries to interpret the accounting, financial and economic information 
expressed in the annual accounts of the company, in comparison with a group of 
companies, with the purpose of: issue an adequate opinion or a diagnosis about the 
past evolution, the current situation in which it is located and the future hopes of the 
company. 
The choice of the company Pharma Mar, SA has been taken for the great contribution 
it has in the pharmaceutical industry and, especially, for the innovative way in which it 
has been investigated in the search for new medicines, since it uses organisms of 
marine origin to try to find a cure for the 21st century disease, cancer. 
On the other hand, the choice of the company Grifols is mainly due to its good position 
in the current market and the expected profitability offered by the company. In addition, 
this company was a pioneer in blood transfusions from a distance and in opening the 
doors of the first private blood and plasma bank in Spain. 
The financial information of the companies has been extracted from the official pages 
of the companies, in which the audited annual accounts of the companies can be 
found. The annual accounts are for the years 2018 and 2017, where 2016 is included. 
In this economic analysis we can differentiate two parts: 
In the first part, it is a brief analysis of the general characteristics of the pharmaceutical 
industry around the world and the general characteristics of the industry in Spain, to put 
the companies in context and for the results detailed in the second step. In addition, a 
brief description has been made of each of the companies, as well as where they come 
from and the steps they have taken to get where they are. 
In the second part, the annual accounts of each company will be analyzed. The study 
of the composition of assets, liabilities, assets and the profit and loss account, the 
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economic and financial profitability of the company, the financial structure they follow, 
the liquidity and solvency and the probability of bankruptcy of the company. 
And to finish the work, we will detail a series of conclusions that have been reached 
through all the characteristics of the industry and, more specifically, analyzing the 

























Global vision of the pharmaceutical sector 
The medicine is one of the most valuable assets for society, helps relieve pain, cure 
diseases, increase life expectancy and improve the quality of this. Behind all this great 
work are the big companies of the pharmaceutical sector, a great power of the 
economy and a great source of qualified employment. 
The pharmaceutical industry is one of the most relevant sectors worldwide, it is 
responsible for monitoring, developing and marketing all the medicines we use today, 
not only for humans but also for animals (veterinary sector). It is an oligopoly, in which 
25 companies control 50% of the industry. Within this sector we can distinguish 
between pharmaceutical laboratories, para-pharmacies, pharmacies and the national 
health and safety agency. 
The main characteristic of this sector is the research and development of new products 
with which health professionals can work (doctors, nurses, etc.). 
The way in which companies in the pharmaceutical industry obtain benefits is partly 
due to the commercialization of their products and, on the other hand, through the 
patent system. 
Globalization has had a positive effect on the benefits of pharmaceutical products, as 
they acquire materials in cheaper countries (developing countries) and also install new 
companies where costs, such as labor and taxes, are cheaper and, finally , they sell 
their products in developed countries that have a greater purchasing power, which 
translates into a higher net income. 
In the sector a very aggressive sales strategy is applied, it is about setting aside the 
small companies that can not compete with the big ones, which have a great 
advantage in the efforts to achieve a more advantageous policy. In addition, 
information on how to obtain the product can be used. Among its strategies we could 
highlight that in many occasions they will carry out deceptive advertising, without taking 
into account how harmful it can be for the consumer. They do not take into account the 
diseases of poor countries, they focus on the countries with more benefits, because 
they have higher benefits with this. 
With the passage of time, companies have adapted to a new technological climate and 
have modernized to meet the needs of the market. Professionals in this sector have 
also decided to train in the field of business management. The pharmaceutical 
12 
 
companies are in charge of producing and marketing their product, therefore, apart 
from their knowledge in the laboratory and the analysis, they need to know the sector in 
which they work, the industry in which they operate, their competitors, its opportunity 
cost and its comparative advantages, among others, so that knowing all this is easier 
for them to take advantage of each situation to reach the client with the best possible 
offer and, therefore, improve their sales and, consequently, their benefits . 
In recent decades, as the years go by, the cost of the investment to develop a new 
drug increases compared to the previous year. In 2014, the cost of research and 
development of a new project was 2.558 million dollars (2.425 million euros), which in 
1979 was 199 million dollars, that is, the cost multiplied by 12.12 in 35 years. 
 
 
Figure 1: Evolution of drug production costs. 
One of the new trends that have emerged in this sector are pharmacies or pharmacies 
"online", where with the emergence of social networks, users through any place and 
time can access the medicines they need. In this way, you can use it to market your 
products and increase your sales, in addition to having the ease of not having to travel 
to obtain the product (as long as these products do not need a recipe). 
"According to an article in March of this 2019 published on the Farmaindustria website, 
research, talent, transparency and collaboration are the keys of the sector. And of 
course, the technology applied to this sector must possess these qualities. " 
In a global vision of the sale of pharmaceutical products, the United States and Japan 
stand out, which increase significantly over time, above all, we must highlight the great 
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evolution that Japan presents from 2011 to 2020 (Prediction), where the result is 
approximately four times greater. 
 
Figure 2: Volume of sales of the pharmaceutical industry in different areas of the world between 2011 and 

















The pharmaceutical sector in Spain 
In the Spanish economy, the pharmaceutical sector is one of the key sectors, as well 
as its capacity for innovation and investment in R & D projects, as well as the capacity 
it has to generate work. 
This sector has developed extraordinarily in recent years, both in Spain and in the 
world, with a huge volume of benefits. 
Every time you have the project to start manufacturing a new medicine, you must take 
into account that it is a very long process and that it requires a large investment, where 
its success is unpredictable (we do not know the degree of acceptance of the product a 
priori by the Consumer and if its commercialization is approved), in Spain public 
spending has become a project of this type by 30%, with an upward prognosis. 
The reality of the pharmaceutical industry in Spain is that it has more than 40,000 
professionals affected by this industry, which are distributed among the 212 companies 
in the sector (national and Spanish multinationals), of which the majority of workers are 
women, and In addition, 93% of people working in this sector have an indefinite 
contract. With respect to the direct employment of the pharmaceutical sector, there are 
200,000 people, and for each person associated with this activity there are four people 
who acquire the work indirectly, so that there are 800,000 people working directly or 
indirectly in the pharmaceutical industry. 
 
Figure 3: General characteristics of the pharmaceutical industry (Pharmaindustry). 
In addition, it is the leading sector in I + D research in Spain and a leader in productivity 
per employee, which is more than twice the industrial average. With 1,085 million euros 
invested in research centers and hospitals, it is one of the most demanding economies 
in our country. 
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The investment in I + D has represented in the pharmaceutical industry, which will 
position itself as a leader in this discipline. This investment has always been very high, 
although the years in which the financial crisis lasted (2008-2014) decreased with 
respect to previous years, until 2016 reached the maximum investment figure cited 
above (1,085 million). 
 
Figure 4: Evolution of I+D expenses 2009-2016 in Spain. 
In 2017, Spain reached 1,147 million euros in investment in research and development 
of the pharmaceutical industry, 5.7% more than the previous year according to 
"Farmaindustria". These data support the idea of an upward trend in companies in the 
pharmaceutical industry. It represents 20% of the total Spanish investment in I+D, and 
is the leading sector in investment in research and development according to the INE 
(National Institute of Statistics). 
 
Figure 5: National Institute of Statistics. Innovation in companies. 
The investment in research and development of the pharmaceutical companies is very 
different according to the autonomous community to which it is destined. The 
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communities of Madrid and Catalonia stand out, receiving more than one hundred 
million euros each, while, however, in La Rioja they do not reach one million euros and 
in 11 of the communities they do not exceed 10 million euros. The Valencian 
community receives only 31.5 million euros and is the fourth community that receives 
the largest investment. 
 















PHARMA MAR S.A. 
In 1939 the company Zeltia was founded, a company dedicated to the research and 
development of medicines of animal origin and local medicinal plants. In 1963 it goes 
public and is sold in the Spanish market, and in 1998 it starts trading on the continuous 
market. In 1964, three new companies were founded: Zeltia Agraria (agricultural 
industry), ICI Farma (pharmaceutical industry) and Cooper Zeltia (chemical and 
veterinary industry). In 1986 Pharma Mar was founded. 
Pharma Mar S.A. is a company of the Spanish pharmaceutical industry (Art. 8 LIS), 
incorporated on April 30, 1986 as a public limited company, whose fiscal domicile 
corresponds to Madrid. 
The company's main activity is research, development and commercialization of 
bioactive principles, especially of marine origin, for its application in human medicine 
and especially in antitumor, antiviral, immunodulatory and tropical diseases areas, as 
well as management, support and promotion of its investees, mainly in the chemical 
and biopharmaceutical sectors. 
In 2007, the company received the acceptance of the European Commission to market 
its first compound, as a pioneer in marine medicines with Yondelis, indications of 
cancer, specifically for the ovary and soft tissues. This report has spread across the 
globe in more than 80 countries. 
The majority of the planet (70%) is composed of water (seas, oceans, rivers, lagoons 
...), and most of the living beings live in this habitat (80%). Since the beginning of 
evolution, marine organisms have developed new forms of survival, attack, 
communication and, above all, defense, that is why this society focuses on the 
research of marine organisms for their new drugs. 
On October 30, 2015, the inverse merger between Zeltia and Pharma Mar was carried 
out, that is, since then the company of Zeltia has ceased to exist and Pharma Mar has 
become the parent company of the group. To carry out this takeover, the shareholders 
of Zeltia received an action from the new parent company for each share they had 
previously in the old company. Once the company is absorbed, Pharma Mar will be 
quoted on the stock exchange and will give its name to the group's price. 
Currently, it has six subsidiaries within the European Union (Spain, France, Germany, 
Italy, Belgium and Austria), and with a center of activity in the United States, number of 
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countries that it hopes to increase with internationalization, in order to : Being able to 
take care of the medical needs of each country inspired by the sea. 
 























In 1940 in Barcelona, Dr. Josep Antoni Grifols i Roig founded together with his children 
some laboratories (Grifols), whose main activity was clinical analysis, manufacture of 
vaccines and blood transfusions. In 1909 he founded his first laboratory of analysis, 
also located in Barcelona, precursor of the Grifols Laboratory. 
Its mission is to improve the well-being and health of all people in the world, through 
plasma-derived medicines, as well as providing hospitals, pharmacies and 
professionals with the necessary tools. 
With the difficulty of being able to maintain sterility in the samples, in 1916 Grifols i 
Roig has different models of the same analysis instrument (Vacuum flébula), which 
serves to obtain the asepsis condition when extracting the samples. 
A root of the First World War, in 1928, after the doctor's research into international 
blood transfusions, which patents the first instrument to perform blood transfusions 
remotely, transfleche flébula. 
In 1945, the first private blood and plasma bank in Spain, the Hemobanco of the Grifols 
Laboratories, for the interest of finding a better technique for plasma conservation. And 
in 1951, for the first time in the world, a new method was obtained to obtain plasma, 
the plasmaferesis technique in humans. 
In 1960 the first American partners joined the company. These new partners will be in 
charge of managing the blood banks in the United States, and after with the agreement 
of Dade Reagents, they decide to market their products in Spain under the name of 
Dade-Grifols. 
In 1987 there was an internal organizational organization, after the generational 
change of the company. This new transformation, the company becomes the Grifols 
Group, where there are productive companies of clinical diagnosis, production of 
plasma-derived products, parental solutions and the company involved in marketing the 
products. A year later, the company begins to expand outside Spain and opens its first 
subsidiary in Portugal. 
In 2002, the company acquired the SeraCare company and its 43 plasma donation 
centers in the United States. The following year, in Los Angeles, it acquires the assets 
of Alpha Therapeutic Corporation-Mitsubishi, with its plasma fractionation plant. 
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Grifols starts trading on the continuous English market starting in 2006, and already in 
2008 it is included in the IBEX35 listing, and in 2011, after acquiring a new American 



















































Financial and Economic Analysis 
In this second part of the work, an economic and financial analysis will be carried out of 
the companies that have been selected to carry out this work, Pharma Mar S.A. and 
Grifols S.A. 
To carry out this analysis, the individual annual accounts (Balance Sheet, Profit and 
Loss Account, State of Changes in Equity, Statement of Cash Flows and 
Memorandum) of each of the companies selected have been used, during the period 
from 2016 to 2018. These official accounts have been obtained through the official 
websites of each of the companies, where all the necessary financial information is 
provided.  
The annual accounts of the two companies have been prepared in accordance with the 
regulations of the Account General Plan, since they are individual accounts, in the case 
of this accounts quote in the stock market, the must have to present the annual 
accounts according to international accounting regulations, NIFF-UE. In addition, the 
annual accounts of both companies have been audited by audit companies that are 
part of the "Big Four", Pharma Mar has been audited by PwC (Price Water house 
Coopers), and Grifols has been audited by KPMG. The opinion issued by the auditors 
is favorable for the two companies in the period of time studied, for this the financial 
information is reliable to perform the analysis and its respective comparison between 
two companies. 
For two companies to be comparable, they must use the same accounting standards, 
and this is true, the difference between the two is that Pharma Mar is expressed in 
thousands of Euros while Grifols is expressed in Euros. In order to be perfectly 
comparable, the annual accounts of Pharma Mar in Euros have been expressed, as 
has Grifols. 
PATRIMONIAL ANALYSIS 
According Archel, Lizarraga, Sánchez y Cano (2015) The purpose of the patrimonial 
analysis is to study the composition, evolution, tendency and balance between the 





Within Balance three blocks are differentiated according to PGC (2015): 
1. Assets: property, rights and other resources economically controlled by the 
company, as a result of past events, the expectation of the company is had 
benefits of economic returns in the future of these. 
2.  Liabilities: current obligations arising as a result of past events, for whose 
extinction the company expects to divest itself of resources that may produce 
profits or economic returns in the future. For these purposes, provisions are 
understood to be included.  
3. Net Equity: Included the residual part of the assets once all liabilities have been 
deducted. It includes the contributions made, either at the time of their 
constitution or subsequent ones, by their partners or owners, who do not take 
into account the liabilities, as well as the accumulated results or other variations 
that affect them. 
The first step is to perform the vertical and horizontal analysis of the parts in the 
balance sheet. According to G. Goméz (2001), the vertical analysis consists in 
determining the percentage of each item of the balance sheet with respect to the total, 
that is, the calculation of the asset items and in what percentage they make up the total 
assets, and in what percentage the items of the liability and net equity make up the 
total of the sum of this. It is a static analysis, since it focuses on a single period. 






Figure 8: Vertical analysis of Pharma Mar assets 
As can be seen, the no current asset hold most of the total Assets with 84.65% in 
2018, and within this the greatest patrimonial mass fixed by intangible immaterial, 
especially development, which forms 48.44% in 2018. These results match the general 
characteristics that the industry shows, because these companies need a lot of 
inversion that for the development of new products. On the other hand, the current 
assets in 2018 are 15.35% over the total Assets, they are distributed mainly between 
Cash and other equivalent assets (6.25% in 2018), Trade debtors and other accounts 





Figure 9: Vertical analysis of Pharma Mar liabilities and equity. 
In this second Block of the Balance, Net Equity and Liability, is formed more or less by 
half of each one, being the net patrimony a 54.66% in 2018 of the total, where the own 
funds are almost the total of this percentage (53.79% in 2018), Non-current liabilities is 
22.14% in 2018, current liabilities is 23.19% in 2018, formed by creditors and other 
accounts payable (10.54% in 2018) and current debt ( 9.81% in 2018). 






Figure 10: Vertical analysis of Grifols assets. 
In this case, the non-current asset comprises almost the entire asset value (96.79% in 
2018) and this is formed in most of the group's investments and non-current associated 
(94.69% in 2018), while current assets only cover 3.2% of total assets, made up mostly 
of commercial debtors and other accounts receivable (1.13% in 2018) and investments 






Figure 11: Vertical analysis of Grifols liabilities and equity. 
Within the second block of the Balance Sheet, Net equity and Liabilities, the Net Equity 
forms 33.47% in 2018 over the total, and within it are the own funds that make up 
almost the total of this. The no current liability is more or less the half of the total, being 
63.35% in 2018 over the total, and the current liabilities represent 3.17% in 2018 of the 
total, composed mainly of non-current debt (33.86% in 2018) and debt whit group 
business and associates in long term (29,45 in 2018), fundamental compound by 
commercial Creditors and Other accounts receivable (1.62% in 2018). 
According to G. Gomez, the horizontal analysis consists of comparing the parts of the 
balance sheet in two or more consecutive periods, and comparing the increases and 
decreases that have occurred in the analyzed years. It is a dynamic analysis and is 
related to changes in time periods. 
Analyzing the horizontal index of the company of Pharma Mar S.A. you get the data 













Figure 12: Horizontal analysis Pharma Mar. 
All horizontal indices have a negative sign, which means that they have decreased 
compared to the previous year. In H2017, the accounting data is compared with the 
2016 data, as can be seen the largest decline in this company occurs in 2017 in net 
worth, which decreases by 43.96% over the previous year, and the non-current assets 
that decrease by 42.83% with respect to the previous year (2016). In H2018, however, 
except the no current assets that decreases by 9.91%, the other parts decrease by 
more than 10% with respect to the previous year (2017), and that decreases the non-
current assets in a  greater proportion by 18, 49%. 
Analyzing the horizontal index of the company of Grifols S.A. you get the data from the 
following figure. 
 
Figure 13: Horizontal analysis Grifols. 
 
In this company, you can see that in 2017 there is a positive effect with respect to 
2016, since all of its items increase, highlighting mainly the increase in liabilities by 
618% compared to 2016. As can be seen in the Appendix, this increase is due to an 
“descomunal” increase in debts. And in 2018, most of the parts were reduced, although 
not in an exorbitant way, highlighting the decrease of the current assets by 14.81%. 
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ANALYSIS OF MANEUVER FUND AND OPERATING NEEDS OF FINANCING. 
According to D. Lorenzana (2012), the maneuver fund is the difference between 
current assets and current liabilities, that is, the differences that exist between short-
term collection rights and short-term payment obligations. The normal and 
recommended is that the working capital is positive. 
On the other hand, the operational financing needs are the net investments that the 
company needs to carry out its current operations once the financing generated by the 
operation itself has been deducted, according to B. Oliete (2012). 
Pharma Mar S.A. 
 
Figure 14: Maneuvering fund of Pharma Mar. 
In the company PharmaMar S.A., in 2016 the company presents a positive working 
capital, which is an efficient result for the company, since it can face its short-term 
obligations with the rights it has in the short term. In 2017, the situation worsens to a 
great extent, since positive funds in the previous year obtain a negative fund, because 
its short-term rights decrease by half. Finally, in 2018 a negative maneuver fund was 
also obtained, although better than that obtained in the previous year, due to its short-
term payment obligations have decreased. 
 




In 2018 and 2017, the company present a negative maneuver fund and the need to 
count on the help to continue with the usual operations of the company, and in 2016, 
although a priori it will present a favorable result for having a positive result, also they 
need financing operational. 
Grifols S.A. 
 
Figure 16: Analysis of maneuvering fund of Grifols. 
The company Grifols SA, presents in the three periods analyzed in the maneuver fund 
a positive result, in the first instance it can be said that the company is in a good 
economic situation, that it can face its short-term obligations with its short-term rights. 
In addition, this is increasing in the length of the analyzed periods; therefore a better 
result is obtained with the passage of time. 
 
Figure 17: Analysis of operating needs of Grifols. 
In the company Grifols S.A. in all the periods analyzed, the financing operations needs 
are lower than the maneuver fund, so the company must not resort to outside financing 
to continue with its normal operations of the company, it is in a good financial situation 




ANALYSIS OF RENTABILITY 
According to J.P. Ballesta (2002), the economic profitability (ROA) of a company or the 
profitability of the investment is a measure, referenced at a specific time, where the 
performance of the assets of a company is independent of how they have been 
financed. Specifically, it is the ability of the company's assets to generate value 
independently of its financing. 
Economic profitability is defined as Earnings before Interest and Taxes divided whit 
total Assets. 
 
Figure 18: Economic profitability formula. 
The Benefit before Interest and Taxes is the result that generate all the investments, 
that is, all the operating expenses and income and the financial expenses and income. 
Within Balance is under the heading of Profit and Loss that is denominated equal. The 
denominator refers to the media of the total assets in the years in which it is analyzed. 
Regarding economic profitability, the higher the ratio that represents a better situation 
will be found. This must be quite large because a part of it wills retribution to the debt 
and to the shareholders. On the other hand, if this is zero or negative, it has a harmful 
effect for the company, since it would mean that the company does not manage to 
obtain the expected return through its assets through its main activity. 
 












The company of PharmaMar S.A. it presents a negative economic return in the periods 
of 2018 (Point 1) being exactly -9.18%, and 2017 (Point 2) being -33.07%. Therefore, 
the performance of the company has a nefarious performance, although the situation 
has improved from one year to the next. 
 
Figure 20: Economic profitability of Grifols. 
The company of Grifols S.A. it presents a positive economic return in the two periods, 
in 2018 it presents a 9.07% (Point 1), and in 2017 it presents a 12.37% (Point2). To 
which the company's returns are favorable for the economic situation of the company, 
although from 2017 to 2018 it has reduced its profitability, a factor that it must take into 
account to take into account the operational activities in the future. 
As can be seen, the company of Grifols SA presents a better economic situation in 
relation to the company Pharma Mar SA that its returns are much higher, and in 
addition, a difference of Pharma Mar, its returns are positive, the necessary condition 
for the profit os the company through its main activity. 
Although this is the most normal way to calculate the ROA, we can verify by other 
procedures that this has been calculated correctly, which is the case of the 
multiplication of the margin by rotation. 
The margin can be calculated as a result before of interest and taxes, used to also to 
calculate the ROA, divided by the net amount of the billing. While the rotation can be 
calculated as, the net amount of the turnover, between the total assets means (also 
used in the calculation of the ROA). In this way we verify that the calculated ROA of 











Figure 21: Verification of economic profitability. 
Once these data have been calculated, the interannual variation of the ROA is 
analyzed. This part shows how the factors that affect the economic profitability of the 
company have varied between the years analyzed. 
 
Figure 22: Annual variation of economic profitability. 
The economic profitability in the company PHARMA MAR S.A. has increased by 
23.90% from 2017 to 2018. This is because the company's margin has increased by 
120.33% and turnover by 9.33%. Therefore, although we must take into account that 
they have a negative profitability, the company has improved significantly from one 
year to the next, so it is a positive aspect. 
Economic profitability has been reduced over time, because both the rotation and the 
margin have also been reduced too (-3.87% and -3.07% respectively). Therefore, 
although the company has a good economic return in the two periods, this account has 
been reduced over time, and this is a negative aspect. The fear that it will decrease 
even more in the future. 
The interannual variation of the ROA can be made through the margin effect, the 
rotation effect and the joint effect. The margin effect is the rotation of the previous year 
multiplied by the margin variation of that year. The rotation effect is the multiplication of 
the margin of the previous year by the variation of this year's rotation, and the joint 
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effect is the multiplication of the variation of the margin by the variation of the rotation. 
These three calculated items are added and the ROA variation check is obtained, 
which must be the same as the one calculated previously to make sure that it has been 
calculated correctly. 
On the other hand, the financial return (ROE) or the return on equity is a measure 
within a specific period of time, the yield obtained from the property rights of the 
company with the independence of the results. This profitability is what the 
shareholders and owners of the company perceive, which the managers try to 
maximize it for the interest of the owners. A poor financial return limits the accessibility 
to new funds for the company. On the one hand, investors will not be attracted to invest 
in the company if it does not have a good financial return and another part, it is 
indicative that the funds are generated internally, According J.P. Ballesta (2002). 
The financial profitability of a company is calculated by the coefficient between Benefits 
before Taxes divided by total net equity of the company. 
 
Figure 23: Financial profitability formula. 
The financial profitability can be expressed in another way to analyze it more closely 
as: 
 
Figure 24: Comparation between economic and financial profitability formula. 
 
The ROE can be broken down as the sum of the economic return, plus the 
differentiation between the financial return of the company and the fixed costs, 
multiplied by the company's liability between the net equity. 
The liability between equity is the effect of financial leverage, that is, the amount of 
debt with which they are financing. Related to this, we must take into account financial 
flexibility, that is, the point where the company can be financed by debt without the 
company having problems to face it. The sign of this factor will depend on whether the 
fixed costs of the company are superior to the economic profitability it has. 
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A company that is not indebted, its economic profitability will coincide with the financial 
profitability. 
Pharma Mar S.A. 
 
Figure 25: Financial profitability of Pharma Mar. 
The company of Pharma Mar S.A. It presents a negative financial return because the 
result of the company is also negative, and therefore when applying the equation the 
result obtained is negative. A negative result reflects that shareholders are not 
receiving the return expected to be investing in the company, and also produces new 
investors feel rejected by it by not offering a good financial return. 
In 2017 a financial return of -54.56% is obtained and in 2018 of -18.96%, so although in 
both years it presents a negative situation with respect to financial profitability, at least 
it has managed to improve and in a large measure. The company has a large debt, that 
is, it is very leveraged, since in 2017 this factor represents 60.20% and in 2018 it even 
increases further reaching 82.14%. The margin of leverage is negative, because the 
ROA (previously calculated is negative), therefore if it is a negative factor you subtract 
something negative, even make it more negative. 
Therefore, since financial profitability is lower than economic profitability, it means that 










Figure 26: Financial profitability of Grifols. 
The company of Grifols S.A. It presents a positive financial return, so that the 
shareholders of the company are obtaining profitability by having their funds invested in 
this company. 
In 2017 a financial return of 22.53% is obtained, and in 2018 it is reduced to 19.97%, 
so although the profitability is positive in both years, the shareholders of the company 
will see reduced profitability obtained and take action on this. As can be seen, the 
company is very leveraged, meaning that a large part of its investments are being 
financed with debt, in 2017 it represents 138.60%, while in 2018 it increases by a large 
amount, representing 213.15% . 
 In this case, the economic profitability of the company is positive and greater than the 
average financial cost of the liability, with which the margin of both years is positive, 
and therefore the financial profitability of the company is higher than the economic 
profitability of the company. 
 Therefore, since financial profitability is greater than economic profitability, it means 
that the average cost of the company's debts is lower than the economic profitability 
that is obtained. As the company is financing part of its assets with outside resources 
(debt) the company has increased its financial profitability. 
According to E. Zamora (2017), the Threshold of Profitability represents the level of 
sales in which the revenues and the costs of the company coincide, that is to say, the 
level of sales with which a null result is obtained, "0", Therefore, it is also known as the 




To calculate this parameter, it will be the quotient of the fixed expenses between one 
minus the variable expenses between the operating revenues of the company. 
 
Figure 27: threshold of profitability formula. 
 
Figure 28: Analysis of threshold of profitability. 
The company of Grifols S.A. although up to now analyzed is the company that is in a 
better economic and financial situation, it needs a higher level of sales compared to 
Pharma Mar S.A to get breakeven (Threshold of profitability). From this point of sales, 
the company starts to have profits; below this company has losses, therefore, the 
company of Pharma Mar S.A. from the level of sales 171,693,970.15 € the company 
starts to have profits, on the other hand, the Grifols S.A. from the level of sales of € 
263,736,026.72 the company starts to obtain benefits. 
But in this point, it can be seen, when comparing this data with the operational income 
of each company, the threshold of profitability of Pharma Mar is higher than his 
operating income. On the other hand, the threshold of profitability of Grifols is lower 







MATURITY PERIOD OF THE COMPANY 
According to S.A. Javier, the average period of maturation of a company is the average 
time that elapses between charging customers for the sale of products (include the 
time of enter the products in the warehose) and payment to suppliers of the company 
for the purchase of a producer to be able to face the operational activity of the 
company. Within the average period of maturation of the company, two aspects are 
distinguished: 
 Period of economic maturity. Referred to the time that lasts the cycle of 
exploitation of the company, that is to say, from the moment in which the entry 
of merchandise in the store of the company takes place until the invoices issued 
to the clients are charged. 
 Period of financial maturity. Referred to the time in which the company takes to 
recover the capital invested in its production process. 
 
Figure 29: Outline of the maturation period. 
The average period of economic maturity is composed of the period of storage of the 
products plus the term of collection to customers. The storage term refers to the time 
that elapses since the raw materials arrive to the company until they are sold and they 
manage to leave the warehouse. On the other hand, the collection period is the time 
that elapses from when the merchandise of the company is sold to the clients until they 
are charged. 
The average period of financial maturity is the difference between the average period 
of economic maturity minus the payment period by the providers. The payment term 
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refers to the time that elapses since the goods are purchased until they are paid to the 
suppliers. 
Pharma Mar S.A. 
 
Figure 30: Maduration period of Pharma Mar. 
Existences rotation is calculated as the quotient between the company's supplies 
between the average existences balance, and the storage term is 365 days 
(corresponding to the calendar year) between the existences rotation. In 2017, 445 
days pass from the storage of the raw materials in the warehouse until the products are 
sold. In 2018 the situation worsens, since they take longer to leave the products, 504 
days. 
Customer rotation is the quotient between the net amounts of the turnover plus the 
VAT (IVA) of the sale between the average balance of customers, and the term of 
collection of customers is 365 days between the rotations of customers. In 2017 it took 
around 104 days to collect the invoices that were issued to customers, in 2018 this 
situation improves significantly since only 41 days pass. 
The average term of economic maturity is the sum of both parameters, in 2017 it is 549 
days, and in 2018 it is 545 days. 
The rotation of suppliers is the quotient between purchases plus the VAT (IVA) borne 
by them among the average balance of suppliers of the company. The payment term is 
the quotient between 365 days between the rotations of suppliers. In 2017, the average 
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term of payment to suppliers is 121 days, and in 2018, the situation improves as the 
payment term increases to 142 days. 
The period of financial maturity is the subtraction between the average period of 
economic maturity and the term of payment to suppliers, which in 2017 is 428 days and 
in 2018 is 404 days. 
The period of financial maturity is positive, so the period that elapses since the 
materials enter the warehouse until it is collected is product is greater than the 




Figure 31: Maduration period of Grifols. 
Existences rotation is calculated as the quotient between the company's supplies 
between the average existences balance, and the storage term is 365 days 
(corresponding to the calendar year) between the existences rotation. In 2017, 756 
days pass from the storage of the raw materials in the warehouse until the products are 
sold. In 2018 the situation worsens, since they take longer to leave the products, 799 
days. 
Customer rotation is the quotient between the net amounts of the turnover plus the 
VAT (IVA) of the sale between the average balance of customers, and the term of 
collection of customers is 365 days between the rotations of customers. In 2017 it took 
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around 9 days to collect the bills that were issued to customers, in 2018 this situation 
gets worse as 10 days pass, that is, one more day compared to the previous year. 
The average term of economic maturity is the sum of both parameters, in 2017 it is 766 
days, and in 2018 it is 808 days. 
The rotation of suppliers is the quotient between purchases plus the VAT (IVA) borne 
by them among the average balance of suppliers of the company. The payment term is 
the quotient between 365 days between the rotations of suppliers. In 2017, the average 
payment period to suppliers is 3783 days, and in 2018, the situation improves as the 
payment term increases to 3967 days. 
The period of financial maturity is the subtraction between the average period of 
economic maturity and the term of payment to suppliers, which in 2017 is -3017 days 
and in 2018 is -3159 days. 
Therefore, as the maturation cycle is shorter than the payment term, the company 
enjoys an excess of assets to meet the payments of the debts. 
According to Holded (2018), financial ratios are tools that are used to analyze the 
financial situation of the company, to know if the company is being managed well / 
badly. 
In this analysis you will see different financial ratios, depending on the financial 




ANALYSIS OF THE FINANCIAL STRUCTURE THROUGH RATIOS 
The debt ratio is a fundamental tool to know the quantity and quality of a company's 
debt, as well as to find out if it is obtaining enough profit to support such a financial 
burden. 
This ratio is calculated through the quotient between the Company's Liabilities and the 
Net Equity. If you want to calculate the short-term debt, you would use the current 
liabilities, and in the long term, the non-current liabilities. D. Espinosa (2011). 
In the figures that will be analyzed next, point 1 




Figure 32: Debt ratio formula. 
The lower this ratio, the more autonomy the company has. The interval that is 
considered optimal for companies is between 0.7 and 1.5. 
Pharma Mar S.A. 
 
Figure 33: Debt ratio of Pharma Mar. 
The indebtedness has been increasing in the company of Pharma Mar with the 
passage of time. In 2016, it has a ratio of indebtedness less to the optimal interval, but 
given that the less this ratio is, the less complications the company has to face its 
debts, they are facing a good situation, because the company will have decided to 
finance itself differently from the debt. In the years 2017 and 2018, the debt increases 
slightly, and in these two years the company is within the optimum range of 
indebtedness, so the company is being financed largely by its debts, but without 
reaching a extreme level that can not stand. This is a good situation, because the 
company increases his profitability whit the debt. 
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Figure 34: Analysis between short and long term in the debt of Pharma Mar. 
Within the debt, we have short-term debt and long-term indebtedness, which are 
distributed almost identical in both cases in this company. The short-term debt should 
be less long-term debt, as they are debts that have to cope in a short time. And this is 










Figure 35: Debt ratio of Grifols. 
The company of Grifols, presents a drastic change in its indebtedness. In 2016, it has a 
much lower indebtedness than the optimal interval, which, as has been said before, is 
a good result since the company is financing itself in a majority way that is not debt. But 
in the two subsequent years this increases in an exorbitant way, the company is too 
indebted and this directly affects the company. 
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To see how you have to face this debt, you have to analyze what is short term and long 
term. 
 
Figure 36: Analysis between short and long term in the debt of Grifols. 
In 2016, the company is not heavily indebted, and short-term debt is insignificant, so 
the company will have no problems reconciling with it. Once the debt is analyzed more 
closely, we can see that in the short term the debt is small, and that the enormous 
amount that had grown is due to the long-term indebtedness, so the company in the 
short term will not have problems to deal with debts, but must take into account the 
amount of indebtedness that has the long term for the future. Although it should be 
noted that in 2018 the company has a better situation compared to the previous year. 
The Solvency ratio measures the ability of a company to meet its payment obligations. 
This can be calculated as Total Assets divided by Total Liabilities. 
 
Figure 37: Solvency ratio formula. 
The optimal value range in this ratio ranges between 1.5 and 2.5. Between these two 
points the company is in a correct situation to be able to face all its debts, both short 
and long term. If the value is higher than 2.5, it is a situation of attention, since they are 
offering too much guarantee to their creditors. This situation can be resolved by 
borrowing more with external financing. If the ratio is less than 1.5 and greater than 1, it 
is in a situation of caution, since in the face of a bad situation, it could not face its 
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debts. And finally, if this ratio is less than 1, the company is in technical bankruptcy. 
(E.Escrig (2018)). 
 
Figure 38: Analisys between solvency in Pharma Mar and Grifols. 
Both companies are considered solvent. In 2016, Grifols is more solvent than Pharma 
Mar, but both companies are facing a situation of attention, since they are even too 
solvent, and could increase their profitability by borrowing with outside financing. In 
2017, Pharma Mar is within the optimum solvency range, however Grifols is below this 
range, and therefore this situation is dangerous and not knowing how to cope with it 
could lead to a technical bankruptcy. And in 2018, Pharma Mar is still within the 
optimum range even though it has reduced its solvency to a small extent, and therefore 
is in a good situation, and Grifols has managed to improve its situation with respect to 
the previous year and at that time is within the optimal range, so the company is in a 
good solvency situation. 
RATIOS BASED ON LIQUIDITY 
The liquidity ratio or current ratio is a tool used to see the ability of the company to 
meet its short-term payments. To calculate it, it is the quotient between current assets 
among current liabilities. 
 
Figure 39: Liquidity ratio formula. 
 
SOLVENCIA PHARMA MAR S.A. 















1 2 3 
SOLVENCIA PHARMA MAR 
S.A. 
307,22% 222,71% 220,60% 




This ratio must be greater than 1,5. If it is within the range of 1.5 and 2, the company is 
in the optimum liquidity condition. If it is higher than 2, the company has an excess of 
current assets, and could improve its situation if part of it used it correctly. If it is 
between 1.5 and 1, the company could end up in suspension of payments. And in the 
situation that is less than 1, the company would be in suspension of theoretical or 
technical payments. Gonzalo (2018). 
Pharma Mar S.A. 
 
Figure 40: Liquidity ratio in Pharma Mar 
In 2016, the company is above the ideal percentage of liquidity, so in this period the 
company is able to deal with its short-term debts. But in 2017, the company reduces its 
liquidity by 40%, so it is far below being in the optimal range. As has been well said, at 
this point the company would be in a situation of theoretical or technical suspension of 
payments. And in 2018, although it increases slightly, it would be in the same situation 
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Figure 41: Liquidity ratio in Grifols. 
The company has been decreasing its liquidity over the years studied, but at all times it 
is in a good position, so it does not pose any problem for short-term debts and could be 
addressed at all times. The problem of this situation is the future hope, since it has a 
decreasing tendency, in 2018 it is already at the edge of the good situation, and if it is 
expected to follow this trend, in the future it could have complications to face its 
payments short term. 
The Treasury ratio or the acid test is the relationship between the liquid assets and the 
realizable assets of a company with its current liabilities. Therefore, this ratio measures 
the ability of the company to generate sufficient liquidity with the assets available and 
realizable assets to pay the short-term debts. A. Peiro (2010). 
 
Figure 42: Acid test ratio formula. 
The optimal time interval is between 0.75 and 1, this is where the correct situation for 
the company would be found. If the ratio is greater than 1, the company has excess of 
available and is obtaining a less profitability than if it used it adequately. And if the ratio 











Pharma Mar S.A. 
 
Figure 43: Acid test in Pharma Mar. 
In accordance with the current ratio, in 2016 the company is in the right situation to be 
able to meet its short-term payment obligations. But in 2017, it greatly diminishes and 
the company, both in 2017 and 2018, faces a difficult situation in order to be able to 
face its short-term debts. 
Grifols S.A. 
 
Figure 44: Acid test in Grifols. 
As with the current ratio, in 2016 the company has an excess of assets, which by 
allocating it to other activities could increase the profitability of the company, it is 
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sufficiently capable of facing all its short-term debts. As it happens with 2016, in 2017 it 
has an excess of assets (although it has decreased slightly) and should act in the same 
way. And finally in 2018, the company is within the optimum range of the company, and 
therefore is in the best possible situation within this ratio, since it can deal with all the 
short-term debts of the company, and the excesses are destined to other operations 



























In the present work, an economic and financial analysis of two companies of the 
pharmaceutical sector was carried out, in particular the company Pharma Mar SA and 
Grifols SA, in the period from 2016 to 2018. For this purpose, the annual accounts 
have been used of the companies. 
First, an analysis of the patrimonial structure has been carried out through vertical 
indexes and horizontal indexes. From this analysis, it is deduced that the in total Assets 
of the companies, the more part of these are of Non-Current Asset, that is, that the 
greater part of their assets and rights are destined to a lasting form in the company. In 
the case of the equity and Liabilities, in the company Pharma Mar this section is 
divided more or less in the same percentage, and in the company of Grifols, the 
majority corresponding to the non-current liabilities, that is to say the obligations are 
superior to the year, being the obligations less than a year no significant. In addition, it 
should be noted that the company Pharma Mar has seen all its global parts reduced as 
the years passed, On the other hand, Grifols' business in 2017 increased all of its items 
to a large extent, since the assets and the equity and liabilities are increased by more 
than 150%, and in 2018 they fell slightly, not exceeding a decrease in 2%. 
All these patrimonial movements are reflected in the maneuver fund (“Fondo de 
Maniobra”) and also in the operational financing needs. Pharma Mar in 2016 has a 
positive FM but not enough and for that it needs operational financing needs, but due 
to the decrease in the following years, a negative result is obtained, and operational 
financing is also needed. However, Grifols presents in every year analysis of the 
positive maneuver fund, related to the increase of the patrimonial masses that favor, 
although in 2016 it has a positive result, it would not be sufficient and it would need 
operational financing. 
As for the profitability of each company, this analysis is divided into economic 
profitability, financial profitability and the threshold of profitability. The economic 
profitability and financial profitability are completely opposite in both companies. In 
Pharma Mar, both returns are negative both in 2017 and 2018, but in 2018 they 
improved slightly compared to the previous year. In Grifols they are positive in the two 
years, decreasing slightly in 2018. The threshold of profitability is the level of sales that 
the company needs to start having benefits. The company Grifols needs a higher level 
of sales compared to the company of Pharma Mar to begin to have benefits, but we 
must bear in mind that when comparing this data with the operational income of each 
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company, the threshold of profitability of Pharma Mar is higher than his operating 
income. On the other hand, the threshold of profitability of Grifols is lower than its 
operating income and, therefore, it will be easier to reach that level of sales (Grifols). 
Regarding the average period of maturity of a company, it is necessary to differentiate 
the economic from the financial. The period of economic maturity is the period from 
which the raw materials are acquired until we obtain the pay by the customers. This 
term is shorter in Pharma Mar than in Grifols, which means that the company have less 
time the products in the warehouse and collect the pay them in less time than the 
other. And the period of financial maturity is the term of the economic maturation minus 
the term of payment to the suppliers. The term of payment in Grifols is much longer 
than in Pharma Mar, so the company has more time to be able to cope with their debts, 
and therefore, although it has a longer maturity period and takes longer to get its 
products out of storage, it has a better situation with respect to the other company, 
since it has more time to face its obligations. 
Finally, an analysis is carried out by means of ratios, some depending on the financial 
structure such as indebtedness and solvency, and others depending on the liquidity of 
the company, such as the current ratio and test acid. Regarding indebtedness, in the 
company of Pharma Mar has been improving over time, reaching to be within the 
optimum levels of indebtedness, so that the company is in a correct situation in 2018. 
However, Grifols' company has also increased its indebtedness in 2018 with respect to 
2016, and its situation is of attencion since it is too indebted, but as this debt 
corresponds to a greater extent in the long term, initially in the short term he would not 
have problems to deal with his debts, but he has to take into account the long term for 
the future. Regarding solvency, in 2018 the companies are at an optimum level of 
solvency, with Pharma Mar being more solvent than Grifols. 
Regarding the liquidity ratio, the companies that are below the optimum level, and are 
supposed to have problems, being Grifols' liquidity larger than Pharma Mar. But in this 
part it is necessary to take into account the sector that is being analyzed, and therefore 
the level in which it is found is not so problematic. And finally, in the acid test, the 
company Pharma Mar has a bad situation to deal with its problems in the short term 
since it is below the optimum level, on the contrary, Grifols is within this range and 
therefore it is in the ideal situation to deal with your short-term debts. 
In conclusion, once analyzed the economic factors of the activity of the two business 
Grifols S.A. is in a better economic and financial situation at all times, and in the face of 
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